PublicWire | Emerging Market Stock News
  •  Home
  • Technology
  • Medical
  • Energy
  • Cannabis
  • Finance
  • Retail
  • General
  • Podcast
  • Videos
  • Services
  •  Home
  • Technology
  • Medical
  • Energy
  • Cannabis
  • Finance
  • Retail
  • General
  • Podcast
  • Videos
  • Services
No Result
View All Result
PublicWire
No Result
View All Result

Home » Medical » Pfizer and BioNTech request EUA for COVID-19 vaccine in young children

Pfizer and BioNTech request EUA for COVID-19 vaccine in young children

by PublicWire
October 26, 2021
in Medical
Reading Time: 3 mins read
0

Photo: Marko Geber/Getty Images

Pfizer and BioNTech have officially requested that their COVID-19 vaccine be cleared for use among young children.

In a tweet Thursday, Pfizer said the companies submitted their request for an emergency use authorization (EUA) for their vaccine to the U.S. Food and Drug Administration. They are seeking clearance for it to be used among children ages 5 to 11.

The request for EUA will be evaluated during an upcoming Vaccines and Related Biological Products Advisory Committee (VRBPAC) meeting on October 26.

“We know from our vast experience with other pediatric vaccines that children are not small adults, and we will conduct a comprehensive evaluation of clinical trial data submitted in support of the safety and effectiveness of the vaccine used in a younger pediatric population, which may need a different dosage or formulation from that used in an older pediatric population or adults,” Acting FDA Commissioner Dr. Janet Woodcock said in a statement.

WHY THIS MATTERS

The EUA submission comes as no surprise, since the companies said they would seek regulatory approval “as soon as possible” last month, when they released vaccine data for children ages 5 to 11.

The data showed that a smaller dose of Pfizer and BioNTech’s vaccine elicited a similar antibody response and had comparable side effects as seen in people 16 to 25 years of age.

As noted in Pfizer’s tweet, COVID-19 cases among young children are on the rise. During the week of September 30, 173,469 child COVID-19 cases were reported, representing 26.7% of all cases recorded that week, according to the American Academy of Pediatrics.

In the two-week period prior to September 30, there was a 7% increase in the cumulative number of child COVID-19 cases since the beginning of the pandemic, the AAP found.

“With new cases in children in the U.S. continuing to be at a high level, this submission is an important step in our ongoing effort against #COVID19,” Pfizer said in its tweet. “We’re committed to working with the FDA with the ultimate goal of helping protect children against this serious public health threat.”

THE LARGER TREND

In August, Pfizer and BioNTech’s COVID-19 vaccine became the first to receive full approval from the FDA. The vaccine is now marketed as Comirnaty and is approved for the prevention of COVID-19 for those 16 years old and older.

The companies have also gotten a EUA for a booster shot of Comirnaty among certain populations, such as those 65 years of age and older, individuals 18 through 64  at high risk of severe COVID-19 and those aged 18 through 64 whose occupational exposure places them at high risk of serious complications of COVID-19.

Moderna and Johnson & Johnson have also submitted requests to the FDA for booster shot EUAs. The VRBPAC has scheduled meetings for October 14 and 15 to discuss possible booster shot approvals.

Twitter: @HackettMallory
Email the writer: mhackett@himss.org


This post was originally published on this site

Previous Post

Oscar Health teams up with Chicago health systems to offer tech-enabled health plans

Next Post

Cigna divests life, accident and supplemental benefits businesses for $5.75B

PublicWire

At PublicWire, we know the vast majority of all investors conduct their due diligence and get their news online in a variety of ways including email, social media, financial websites, text messages, RSS feeds and audio/video podcasts. PublicWire’s financial communications program is uniquely positioned to reach these investors throughout the U.S. and Canada as well as on a global scale.

Related Posts

Medical

FDA advisory panel recommends Moderna, Johnson & Johnson vaccine booster shots

October 18, 2021
0
Medical

Walgreens invests $5.5B to accelerate new healthcare business segment

October 18, 2021
0
Medical

Mayo Clinic to study respiratory muscle training as long COVID treatment

October 18, 2021
0
Medical

Anthem, Providence tap Vim for value-based care platform deployment

October 25, 2021
0
Medical

Healthcare lost 17,500 jobs in September amid ongoing labor shortage

October 25, 2021
0
Medical

Cigna divests life, accident and supplemental benefits businesses for $5.75B

October 25, 2021
0
Next Post

Cigna divests life, accident and supplemental benefits businesses for $5.75B

Please login to join discussion

Subscribe To Our Newsletter

Loading
Ad
PublicWire | Emerging Market Stock News 24/7 | Investor Relations US Stock Market

© Copyright 2022 publicwire.com

Navigate Site

  • About
  • Contact Us
  • Disclaimer
  • Watch LIVE
  • Privacy Policy
  • Terms and Services
  • Contributors

Follow Us

No Result
View All Result
  • LIVE Investor News Channel
  • Cannabis
  • Energy
  • Finance
  • General
  • Medical
  • Podcasts
  • Retail
  • Technology
  • Videos

© Copyright 2022 publicwire.com

This website uses cookies. By continuing to use this website you are giving consent to cookies being used. Visit our Privacy and Cookie Policy.